Continuous Glucose Monitoring (CGM) Market Report

Continuous glucose monitoring (CGM) is considered a vital and cost-effective tool to manage type 1 diabetes. The adoption of CGM devices by public and private healthcare systems is rising due to the increasing prevalence of diabetes and increased awareness among healthcare professionals and patients about the benefits of CGM, driving the continuous glucose monitoring (CGM) market size and continuous glucose monitoring (CGM) market growth, and is also increasingly used as a critical care patient monitoring product for intensive healthcare settings. Also, patients are increasingly preferring devices that offer continuous monitoring without the need for frequent finger pricks. As per the information provided by WHO, about 422 million people have diabetes globally; the majority live in less economically developed countries, and 1.5 million deaths are directly attributed to diabetes each year. Additionally, the rising geriatric population is accelerating the growth of the CGM market.

Real-time CGM (rtCGM) devices provide real-time glucose readings in order to help diabetic patients and healthcare professionals manage their diabetes more effectively, forming a key part of the continuous glucose monitoring (CGM) market analysis and broader continuous glucose monitoring (CGM) industry analysis. CGM offers convenience by automatically transmitting glucose data to smartphones or other connectivity devices, enabling easier monitoring and management. Evolving lifestyles of people, rising sedentary behavior, consuming unhealthy diets, and high consumption of alcohol and tobacco contribute to the prevalence of obesity, which in turn leads to a rise in prediabetes cases. Overall, the growth of CGM devices is driven by a combination of technological innovation, clinical benefits, patient preference, supportive regulatory environment, and healthcare considerations. CGM market is highly competitive, with well-established players focusing on innovation and market disruption, leading to continuous improvement in CGM technology.

Development and innovation create an opportunity for market players to gain traction. Regulatory agencies are increasingly recognizing the clinical benefits of CGM systems, thus heavily encouraging manufacturers to invest in research and development and leading to market growth. CGM systems provide patients with actionable insights and real-time feedback, fostering greater engagement in self-care and adherence. Within the continuous glucose monitoring (CGM) market segmentation, the CGM system is segmented into sensors, transmitters, and receivers. The sensor segment, particularly glucose sensors, witnesses large avenues, as sensors are small, flexible devices that are inserted beneath the skin, usually on the abdomen or arm. Additionally, the rising prevalence of type 1 diabetes is fuelling the demand for CGM devices due to several advantages such as helping in reducing hypoglycemia and offering real-time data regarding one’s glucose levels, reducing multiple pricks, and improving the level of glycemic control in individuals.

With the help of technology, it has become easier to manufacture CGMs; thus, healthcare guidelines have recently allowed the widespread adoption of CGMs. While some CGMs offer smartphone apps for viewing real-time data on the screen and for users who don’t use a smartphone, CGM devices can send glucose information to a compatible insulin pump as well. With the rising predominance of diabetes around the world, companies are focused on creating modern and forward-looking CGM gadgets that offer superior precision, user-friendliness, and affordability. Furthermore, the future scope of the market looks promising due to the rising adoption of R&D, which is anticipated to open new avenues for growth and innovation in CGM devices and contribute to the growth of the CGM market over the forecast period. Thus, investments in R&D to improve product quality play a vital role.

• Artificial intelligence-powered devices for early detection of potential health issues.
• Ergonomic and subtle wearable CGM devices.
• Consumers shift towards non-invasive and minimally invasive CGM alternatives
• Android monitoring - a combined, portable, and convenient method for monitoring glucose levels.

The high cost of CGM devices, including transmitters and sensors, can be prohibitive to some consumers, particularly in regions with limited insurance coverage or health reimbursement, influencing the continuous glucose monitoring (CGM) market share. As the CGM market is heavily competitive with well-established market players, well-established companies can be a major challenge for new entrants, and companies may face challenges in competing, distribution networks, consumers' trust, and brand recognition. However, as CGM manufacturing requires significant investment and resources to complete the necessary clinical trials and obtain regulatory approval, regulatory factors can also be a barrier to the entry of new entrants.

Traditional blood glucose monitoring (BGM) devices are a major substitute for CGM devices, as they are cost-effective and ergonomic, and some patients may find fingerstick testing to be more convenient or less intrusive than wearing a sensor on their body. Additionally, alternatives for CGM are insulin devices and flash glucose monitoring (FGM) and insulin pen, which can hamper the growth of the CGM market. CGM devices rely on technology; as a result, sometimes CGMs can be inaccurate, which can hinder the adoption of the device by consumers. Depending on the setting of CGM, a user may get several alarms, which can be distressing and lead to burnout, which may also disrupt users' sleep. Also, one of the primary restraints for CGM devices is their cost, as it covers sensors and transmitters, with at-home sensors lasting only for 10-14 days. Thus, manufacturers must balance between affordability and product quality to maintain the growth of the CGM market.

Rising technological advancements have led to the development of more ergonomic CGM transmitters. The integration of wireless connectivity features in CGM offers seamless data transmission to compatible devices such as smartphones and smartwatches, enhancing the overall user experience and shaping the continuous glucose monitoring (CGM) market outlook and continuous glucose monitoring (CGM) market forecast. The increasing adoption of CGM in both clinical and home settings would add to market progression. For instance, in December 2023, Dexcom announced that the Dexcom G7 ergonomic CGM connected to the Tandem t: slim X2 insulin pump with a 30 min sensor warm-up, which allows users to share glucose data with their loved ones or health care teams in real-time through industry-leading remote monitoring capabilities.

Additionally, in May 2024, collaboration between Trinity Partners and Pulse AI resulted in the development of CGM sensor technology, which was focused on incorporating Trinity’s AI-driven health and wellness analytics platform with the CGM technology, which it acquired from Waveform in January. Similarly, addressing developments in the CGM market, the FDA (Food and Drug Administration) cleared for marketing the first over-the-counter (OTC) CGM. The Dexcom Stelo Glucose Biosensor System, which is an integrated CGM (iCGM) intended for individuals aged 18 years and older who do not use insulin. Thus, collaboration and innovations are leading to the expansion of the CGM market.

North America region is dominating the continuous glucose monitoring market, due to the rising prevalence of diabetes, increasing adoption of CGM devices, technological advancements and tech-savvy consumer base. Additionally, the efforts taken by the government to reduce the burden of disease in a larger level is fuelling the demand for the continuous glucose monitoring market. European countries such as Germany and UK leading due to robust healthcare systems and increasing diabetic populations. Asia-Pacific is expected to witness growth during the forecast period, strengthening the continuous glucose monitoring (CGM) market forecast globally. Most of the diabetic patients are addressed in the Asia-Pacific region. The high prevalence of disease in developing countries such as India and China have been fuelling the demand for CGM devices. Moreover, rising healthcare expenditure, and increasing investment in research and development by companies are driving the CGM market.

Geographic Coverage of the Report:

• Segmentation mapping across device types, sensor technologies, and end-user adoption patterns shapes evaluation of the continuous glucose monitoring (CGM) market alongside its parent diabetes care ecosystem, while demand signals highlight real-time monitoring integration across clinical and homecare settings.
• DROT-linked dynamics influence reimbursement sensitivity, sensor accuracy improvements, and patient adherence curves within the continuous glucose monitoring (CGM) market, where CAGR trajectories, Y-o-Y shifts, and decade-scale expansion scenarios are modeled through layered scenario frameworks.
• Regional stratification highlights North America, Europe, Asia-Pacific, and emerging geographies where the continuous glucose monitoring (CGM) market evolves under differing healthcare infrastructure maturity, with country-level forecasts projecting adoption intensity and access-driven growth patterns across the next decade.
• Competitive mapping across device manufacturers, digital health integrators, and biotech entrants defines positioning in the continuous glucose monitoring (CGM) market, while merger and acquisition activity reshapes portfolio consolidation; within the continuous glucose monitoring (CGM) market, share redistribution reflects platform interoperability and innovation velocity.
• Pricing structure sensitivity, procurement cycles, and supply chain resilience collectively define value realization in the continuous glucose monitoring (CGM) market, with distribution channels spanning hospital procurement systems, retail pharmacies, and digital health platforms.
• Technological innovation in wearable biosensors, regulatory compliance pathways, and evolving clinical guidelines shape strategic execution, while the continuous glucose monitoring (CGM) market benefits from integrated data analytics and streamlined value chain coordination across stakeholders.